Search Results

You are looking at 21 - 30 of 271 items for :

  • All content x
Clear All
Free access

Rebecca McGirr, Leonardo Guizzetti, and Savita Dhanvantari

al . 1994 , Furuta et al . 2001 ). By contrast, proglucagon is processed to glucagon-like peptide (GLP)-1 and GLP-2 in the intestine and brain by PC1/3 ( Dhanvantari et al . 1996 , Dhanvantari & Brubaker 1998 , Damholt et al . 1999 ). Glucagon

Open access

Alyce M Martin, Emily W Sun, and Damien J Keating

-like peptide 1 (GLP-1), peptide YY (PYY) and oxyntomodulin (OXM), and glucose-dependent insulinotropic peptide (GIP) secreting K cells. It is now clear that such a classification system is not accurate given the accumulation of evidence that cross-over in

Free access

K K Sidhu, R C Fowkes, R H Skelly, and J M Burrin

Introduction Glucagon-like peptide 1 (GLP-1) is a proglucagon-derived peptide hormone that is synthesized and secreted by intestinal L-cells in response to the ingestion of nutrients and circulates to the pancreas where it stimulates

Free access

L van Bloemendaal, J S ten Kulve, S E la Fleur, R G Ijzerman, and M Diamant

), oxyntomodulin (OXM) and glucagon-like peptide 1 (GLP-1), have been identified as players in the regulation of feeding by relaying meal-related information on nutritional status to the brain. Based on more than three decades of experimental evidence from rodent

Free access

Antonella Amato, Sara Baldassano, Rosa Liotta, Rosa Serio, and Flavia Mulè

Introduction Glucagon-like peptide 1 (GLP1), produced by intestinal enteroendocrine L-cells in response to the ingestion of nutrients ( Schirra et al . 1996 ), is highly insulinotropic and an inhibitor of gastrointestinal motility, effects that

Free access

Neville H McClenaghan, Peter R Flatt, and Andrew J Ball

-cell desensitisation compared with sulphonylureas may occur following prolonged exposure to nateglinide ( Ball et al. 2004 b ). In vivo , insulin secretion can be stimulated by glucagon-like peptide-1 (GLP-1), a hormone of the enteroinsular axis, released

Free access

Hongbin Liu, Yunshan Hu, Richard W Simpson, and Anthony E Dear

Introduction Glucagon-like peptide-1 (GLP-1), an incretin first identified in 1984, has been proposed as a potential candidate target for therapy in the treatment of type 2 diabetes ( Nauck et al . 1993 , Edwards 2005 ). GLP-1, the product of the

Free access

Guillaume Mabilleau, Aleksandra Mieczkowska, Nigel Irwin, Peter R Flatt, and Daniel Chappard

al . 2010 ). Glucagon-like peptide-1 (GLP1) is a gut hormone synthesized and secreted into the blood stream by intestinal endocrine L cells in response to a variety of stimuli ( Wu et al . 2010 ). Biologically active GLP1 is secreted as a 7–37 or 7

Free access

Franca S Angeli and Richard P Shannon

worldwide epidemic, there is a growing demand for new treatments that not only control plasma glucose but also reduce macrovascular complications. Glucagon-like peptide 1 (GLP-1) is a peptide hormone synthesized in and secreted by enteroendocrine L cells in

Free access

Raylene A Reimer

Introduction Glucagon-like peptide-1 (GLP-1) is a gut hormone released from intestinal L-cells in response to food ingestion ( Kieffer & Habener 1999 ). In addition to potentiating glucose-dependent insulin secretion, GLP-1